Advances in CXCR7 Modulators
Department of Pharmaceutical Sciences, Larkin University College of Pharmacy, Miami, FL 33169, USA
Pharmaceuticals 2020, 13(2), 33; https://doi.org/10.3390/ph13020033
Received: 15 January 2020 / Revised: 17 February 2020 / Accepted: 19 February 2020 / Published: 21 February 2020
(This article belongs to the Section Medicinal Chemistry)
CXC chemokine receptor 7 (CXCR7) is a G-protein-coupled receptor that signals through the β-arrestin pathway. Its ligands include interferon-inducible T cell α chemoattractant (CXCL11) and stromal cell-derived factor-1 (CXCL12). It interacts with CXCR4, and the two are associated with various cancers, as well as other disease states such as coronary artery disease, stroke, inflammation and human immunodeficiency virus (HIV). Antibodies and small interfering RNA (siRNA) have shown the utility of antagonists of CXCR7 in these disease states. Although some small molecules were initially reported as antagonists due to their displayed activity, many function as agonists while still producing the desired pharmacologic effects. A potential reason for this contradiction is that effects may be due to elevated extracellular CXCL12 levels. View Full-Text►▼ Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Lounsbury, N. Advances in CXCR7 Modulators. Pharmaceuticals 2020, 13, 33.
AMA StyleShow more citation formats Show less citations formats
Lounsbury N. Advances in CXCR7 Modulators. Pharmaceuticals. 2020; 13(2):33.Chicago/Turabian Style
Lounsbury, Nicole. 2020. "Advances in CXCR7 Modulators." Pharmaceuticals 13, no. 2: 33.
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.